European Commission agrees deal with Janssen for 200 million doses of its COVID-19 vaccine

pharmafile | October 9, 2020 | News story | Medical Communications AZ, AstraZeneca, Janssen 

The European Commission has approved an agreement with Johnson & Johnson for the supply of 200 million doses of Janssen’s coronavirus vaccine. 

The Advance Purchase Agreement will supply the European Union with these vaccine doses, upon approval and authorisation from regulators. The company is also in talks with other national governments and global organisations to make its vaccine candidate, CP-183528, available throughout the world. 

Johnson & Johnson are also setting aside 500 million doses to ensure lower income countries have sufficient access to vaccines, delivered through international schemes. 

Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Offficer at J&J, said: “The COVID-19 pandemic continues to threaten communities worldwide and we have a responsibility to ensure access to our COVID-19 vaccine as soon as we can. We appreciate the Commission’s and the Member States’ support for our COVID-19 vaccine candidate and development efforts.”

J&J is currently testing a single dose regimen of the vaccine in Phase 3 trials, while a second Phase 3 study with a two-dose regimen is expected to start later this year.

This marks the third vaccine agreement between a pharmaceutical company and the European Commission. Sanofi and AstraZeneca have made agreements to provide 300 million doses each. The Commission has also conducted talks with CureVac, BioNTech-Pfizer and Moderna in the pursuit of further deals.

Conor Kavanagh

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

AstraZeneca’s phase 4 trial stopped early after reaching pre-specified criteria

AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after …


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …

Latest content